COVID-19 vaccine effectiveness on variants of concern
(Randomized evidence)

If you want to see all variants, please click here

Beta

Forest plots
(last update: 2022-04-15)

Description of primary studies

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
Alpha
Beta
Gamma
Delta
NCT04636697
Medicago Inc
Hager K, N Engl J Med, 2022

Full text
Full text
Commentary
Virus-Like particle

CoVLP

Placebo

RCT
Phase 3
Adults including elderly with and without comorbidities, with no previous history of virologically confirmed COVID-19, both seronegative and seropositive, at 85 centers in Argentina, Brazil, Canada, Mexico, the UK, and the USA. N=24141 Variant delta:

Some concerns
Details

Full description

Alpha
Beta
Gamma
Delta
NCT04614948
Janssen Pharmaceutical Companies
Hardt K, Lancet Infect Dis, 2022
ENSEMBLE2

Full text
Full text
Commentary
Non replicating viral vector

Ad26.COV2.S Ad26.COV2.S

Placebo

RCT
Phase 3
Adults, healthy or with stable and well-controlled comorbidities, at 125 centers in Belgium, Brazil, Colombia, France, Germany, The Philippines, South Africa, Spain, UK, and USA N=31835
Some concerns
Details

Full description

Beta
RPCEC00000359
Center for Genetic Engineering and Biotechnology (CIGB)
Hernandez-Bernal F, SSRN, 2022
Abdala-3

Full text
Commentary
Commentary
Commentary
Protein subunit

Abdala

Placebo

RCT
Phase 3
Adults, healthy or with controlled co-morbidities and no history of SARS-CoV-2 at 18 centers in Cuba N=48290
Some concerns
Details

Full description

Alpha
Beta
Delta
NCT04649021
Pfizer/BioNTech+Fosun Pharma
Hui A-M, Lancet, 2022

Full text
Full text
Commentary
Commentary
RNA based vaccine

BNT162b2

Placebo

RCT
Phase 2
Healthy adults and those with a pre-existing stable condition, at 2 centers in China. N=960
Low
Details

Full description

Alpha
Beta
Delta
NCT04900467; EudraCT: 2021-002174-52
Moderna;Pfizer/BioNTech
Janssen C, EClinicalMedicine, 2022

Full text
Full text
Commentary
Heterologous vaccination scheme

BNT/mRNA-1273

m1273/BNT162b2

BNT162b2

mRNA-1273

RCT
Phase 2
Adults with no known or suspected history of SARS-CoV-2 infection at 17 centers in France. N=414
Some concerns
Details

Full description

Beta
Delta
NCT04444674
AstraZeneca + University of Oxford
Koen A, medRxiv, 2022
COV005

Full text
Full text
Commentary
Non replicating viral vector

ChAdOx1

Placebo

RCT
Phase 1-2
Healthy adults aged 18–65 years in 7 centres in South Africa N=2130 Variant beta:

Some concerns
Details

Full description

Beta
NCT04533399; PACTR202009726132275
Novavax
Madhi S, Lancet HIV, 2022

Full text
Commentary
Protein subunit

NVX-CoV2373

Placebo

RCT
Phase 2
HIV-negative adults (18 to 84 years) and medically stable HIV-positive adults (18 to 64 years) at 16 sites in South Africa N=4419 Variant beta:

Some concerns
Details

Full description

Beta
Gamma
NCT04764422
The Government Pharmaceutical Organization (GPO); PATH; Dynavax
Pitisuttithum P, medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

NDV-HXP-S 1mcg

NDV-HXP-S 1mcg + CpG1018

NDV-HXP-S 3mcg

NDV-HXP-S 3mcg + CpG1018

NDV-HXP-S 10mcg

NDV-HXP-S 1mcg

Placebo

RCT
Phase 1
Healthy adults without immunosuppression negative for SARS-CoV-2 antibodies at a single center in Thailand N=210
Some concerns
Details

Full description

Beta
Delta
NCT04762680
Sanofi Pasteur+GlaxoSmithKline
Sridhar S, Lancet Infect Dis , 2022

Full text
Commentary
Protein subunit

CoV2 preS dTM 15 mcg

CoV2 preS dTM 10 mcg

CoV2 preS dTM 5 mcg

RCT
Phase 2
Adults with and without prior SARS-CoV-2 infection and risk factors for severe disease at 20 centers in the USA and Honduras N=722
Some concerns
Details

Full description

Beta
Delta
ISRCTN27841311; EudraCT 2021-001275-16
Pfizer BioNTech + Fosun Pharma / Novavax / Moderna + NIAID
Stuart A, Lancet, 2021
Com-COV2

Full text
Commentary
Commentary
Protein subunit

BNT/NVX-CoV2373

BNT/mRNA-1273

BNT162b2

RCT
Phase 2
Adults over 50 years previously vaccinated with one dose of BNT162b2 at 9 centres in the UK N=532
Some concerns
Details

Full description

Beta
Delta
ISRCTN27841311; EudraCT 2021-001275-16
AstraZeneca + University of Oxford / Novavax / Moderna + NIAID
Stuart A, Lancet, 2021
Com-COV2

Full text
Commentary
Commentary
Protein subunit

ChAd/NVX-CoV2373

ChAd/mRNA-1273

ChAdOx1

RCT
Phase 2
Healthy adults over 50 years previously vaccinated with one dose of ChAdOx1 nCoV-19 in 9 centres in the UK N=540
Some concerns
Details

Full description

Beta
NCT04368728
Pfizer/BioNTech+Fosun Pharma
Thomas S, N Engl J Med, 2021

Full text
Commentary
Commentary
RNA based vaccine

BNT162b2

Placebo

RCT
Phase 2-3
Children (>=12Y yo), adolescentes and adults, with no history or SARS-CoV 2 infection at 152 sites in Argentina, Brazil, Germany, South Africa, Turkey and USA N=44165 Variant beta:

Some concerns
Details

Full description

Beta
Delta
RPCEC00000354
Instituto Finlay de Vacunas
Toledo-Romani ME, medRxiv, 2022

Full text
Full text
Commentary
Protein subunit

FINLAY-FR-2

Placebo

RCT
Phase 3
Adults in medically stable condition with no self-reported previous COVID-19 infection at 48 centers in Cuba N=29352
Some concerns
Details

Full description

Alpha
Beta
Delta
RPCEC00000347
Instituto Finlay de Vacunas
Toledo-Romani ME, Med, 2022

Full text
Commentary
Commentary
Commentary
Protein subunit

SOBERANA 02/SOBERANA plus

Adjuvant

RCT
Phase 2b
Healthy adults with no known or suspected history of COVID-19 at 2 centers in Cuba. N=810
Some concerns
Details

Full description